XB 628
Alternative Names: XB-628Latest Information Update: 16 May 2025
At a glance
- Originator Invenra
- Developer Exelixis
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 May 2025 Phase-I clinical trials in Solid tumours (Recurrent, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06952010)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Mar 2025 US FDA approves IND application for XB 628 in Cancer